Fc receptor News and Research

RSS

How does hybrid immunity shape humoral immune response to SARS-CoV-2?

In a recent study posted to the medRxiv* preprint server, researchers illustrated that hybrid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity widens effective humoral signatures of SARS-CoV-2 vaccinations.

6 Jul 2022

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

A recent article posted to the bioRxiv* preprint server identified numerous efficacious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies from convalescent SARS-CoV-2 patients.

23 Jun 2022

BNT162b2 vaccine induces robust SARS-CoV-2 immunity in children

In a recent study posted to the medRxiv* pre-print server, researchers evaluated coronavirus disease 2019 (COVID-19) vaccine-induced humoral immune response in five to 11-year-old children.

23 May 2022

Cost-effective ovine antibody-based therapy against SARS-CoV-2 infection

A recent study published in the journal Antiviral Research explored alternative sources of polyclonal antibodies against SARS-CoV-2, which would be more cost-effective, amendable to regulatory approval, and widespread use.

12 May 2022

Developing and manufacturing custom recombinant antibodies for R&D

In this interview, Dr. Linlin Zhang, technical specialist for Sino Biological Europe, discusses how Sino is expanding its product offerings into the European market and outlines its process for developing and manufacturing custom recombinant antibodies for their clients.

From Sino Biological Inc. 6 Apr 2022

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA)-1273 coronavirus disease 2019 (COVID-19) vaccines.

4 Apr 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

Rubella antibodies vs. COVID-19

A new study describes a potential relationship between antibody titers against the rubella virus and the severity of COVID-19.

22 Mar 2022

Convalescent antibodies do not enhance SARS-CoV-2 infection

Researchers investigated whether antibodies enhance severe acute respiratory syndrome coronavirus-2 infection.

16 Mar 2022

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Researchers conducted a comprehensive and systematic analysis of functional SARS-CoV-2 antibody profiles in a controlled randomized trial of severe COVID-19 hospitalized individuals treated with COVID-19 CCP.

25 Feb 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

Sexually dimorphic placental antibody transfer during SARS-CoV-2 infection

In a paper recently published in the journal Science Translational Medicine by Bordt et al. (October 19th, 2021), maternal SARS-CoV-2 infections are studied with particular regard to maternal-fetal antibody transfer and virus-induced placental interferon responses, finding a sexually dimorphic response that results in lesser antibody transfer to the male fetus.

26 Oct 2021

Immune response to mRNA COVID vaccines delayed in pregnant women

Researchers in the United States have conducted comprehensive profiling of humoral immune responses in pregnant, lactating, and non-pregnant women following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination to probe differences in vaccine-induced immunity.

25 Oct 2021

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

29 Sep 2021

Neutralizing monoclonal antibodies provide Fc receptor-independent SARS-CoV-2 protection in Hamsters

A study published in the journal mBio analyzes the capacity of the neutralizing MAb 2B04 to protect different antibody titers.

16 Sep 2021

New computational approach may predict how individuals are likely to respond to vaccines

In an advance that sheds light on why certain vaccines may influence people differently, a new computational approach developed at the University of Michigan may predict how individual patients are likely to respond.

2 Sep 2021

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected individuals often suffer from thrombocytopenia, a condition associated with low platelet counts. The cytokine thrombopoietin regulates platelet count. Previous studies have reported that thrombocytopenia can increase the coronavirus disease 2019 (COVID-19) mortality rate by about five times.

16 Aug 2021

Could the activation of FcγRIII/CD16 by anti-spike SARS-CoV-2 antibodies independently determine COVID-19 severity?

A team of scientists from Germany recently investigated whether hyperactivation of immune receptors that recognize the Fc part of an IgG molecule (FcγR) can lead to immunopathologic changes in coronavirus disease 2019 (COVID-19) patients. They have observed that hyperactivation of FcγRIII (CD16) by proinflammatory IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can significantly contribute to COVID-19 related immunopathology.

28 Jun 2021

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A new study in the journal Nature Communications describes the process of converting a SARS-CoV-2 antibody into a multivalent form, thus enabling it to bind at various different points with its epitope.

21 Jun 2021

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Researchers in the United States have developed stabilized immunogens presenting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may improve the scalability of RBD-based coronavirus vaccines.

18 May 2021